Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

450 PREDNISOLONE
PREDNISOLONE
Trade names: Blephamide (Allergan); Delta-Cortef (Pharmacia);
Hydeltrasol (Merck); Inflamase (Novartis); Pediapred (UCB);
Prelone (Teva)
Indications: Arthralgias, Asthma, Dermatoses, Ophthalmology
(many others)
Category: Corticosteroid, systemic
Half-life: N/A
Clinically important, potentially hazardous interactions
with: aluminum, carbamazepine, carbimazole, cyclosporine,
daclizumab, diuretics, etoposide, etretinate, grapefruit juice,
indomethacin, isoniazid, itraconazole, ketoconazole, licorice, live
vaccines, methotrexate, naproxen, oral contraceptives,
pancuronium, phenobarbital, phenytoin, rifampicin, theophylline,
troleandomycin
Reactions
Skin
Acanthosis nigricans (sic)
(2000): Ozerdem U+, Am J Ophthalmol 130(2), 240
Acne
(2004): Escher JC, Eur J Gastroenterol Hepatol 16(1), 47
(2003): Richardus JH+, Lepr Rev 74(4), 319
Acute generalized exanthematous pustulosis
(2006): Buettiker U+, Dermatology 213(1), 40
Allergic reactions
(2000): Bircher AJ+, Dermatology 200(4), 349
(1999): Burova K+, Br J Dermatol 141(3), 597
Atrophy
Bruising
(2001): Walsh LJ+, Thorax 56(4), 279
Dermatitis
(2000): Bircher AJ+, Dermatology 200(4), 349
(2000): Harris A+, Australas J Dermatol 41(2), 124
(1998): Isaksson M+, Am J Contact Dermat 9(2), 136
Erythema
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
(1998): Alexiou C+, Arch Otolaryngol Head Neck Surg
124(11), 1260
Erythema multiforme
(2004): Sen P+, Ann Acad Med Singapore 33(6), 793 (recurrence)
(1999): Lew DB+, Pediatr Dermatol 16(2), 146
Exanthems
(2005): Padial A+, Allergy 60(5), 665
(2000): Bircher AJ+, Dermatology 200(4), 349
(2000): Chew AL+, Cutis 65(5), 307
Kaposi’s sarcoma
(2004): Elliott AM+, JInfectDis190(5), 869
(2001): Sato-Matsumura KC+, Br J Dermatol 145(4), 633
(1997): Halpern SM+, Br J Dermatol 137(1), 140 (with
azathioprine)
Pruritus
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
(1998): Alexiou C+, Arch Otolaryngol Head Neck Surg
124(11), 1260
Psoriasis
(2006): Elston GE+, Clin Exp Dermatol 31(1), 133 (pustular)
(generalized)
Squamous cell carcinoma
(1999): Ahuja M+, Am J Kidney Dis 34(3), 521 (with azathioprine)
Stevens–Johnson syndrome
(2003): Jo DS+, Pediatr Nephrol 18(9), 959
Thinning
(2003): Schou AJ+, J Pediatr Endocrinol 16(7), 973
Toxicoderma
(1996): Mathelier-Fusade P+, Ann Dermatol Venereol 123(8), 453
Urticaria
(2005): Padial A+, Allergy 60(5), 665
Hair
Hair – hypertrichosis
Eyes
Cataract
(2003): Richardus JH+, Lepr Rev 74(4), 319
(2001): Walsh LJ+, Thorax 56(4), 279
(1998): Dasgupta B+, Br J Rheumatol 37(2), 189
Chorioretinopathy
(2004): Koyama M+, Ophthalmologica 218(2), 107
(1997): Wakakura M+, Jpn J Ophthalmol 41(3), 180
Diplopia
(1997): Brocq O+, Presse Med 26(6), 271
Glaucoma
(2003): Richardus JH+, Lepr Rev 74(4), 319
(1995): Kong L+, Yan Ke Xue Bao 11(1), 53
Ocular burning
Ocular pain
Ocular pressure
(2004): Tham CC+, Am J Ophthalmol 137(1), 198
(2000): Ozerdem U+, Am J Ophthalmol 130(2), 240
Ocular stinging
Vision blurred
(2000): Ozerdem U+, Am J Ophthalmol 130(2), 240
Other
Adverse effects (sic)
(2004): Gotzsche PC+, Cochrane Database Syst Rev f(3), CD00
Anaphylactoid reactions/Anaphylaxis
(2005): Erdmann SM+, JAmBoardFamPract18(2), 143
Candidiasis
(2002): Tanaka H+, Pediatr Int 44(6), 702
(2001): Walsh LJ+, Thorax 56(4), 279
Infections
(2004): Lamb SR+, Clin Exp Dermatol 29(3), 254
(2003): Kunisada M+, Int J Dermatol 42(9), 710
(2003): Richardus JH+, Lepr Rev 74(4), 319
(2002): Han BG+, Yonsei Med J 43(5), 686
(2001): Polnau U+, Z Rheumatol 60(1), 41
(2001): Yasumi M+, Rinsho Ketsueki 42(8), 601
(2000): Hovi L+, Bone Marrow Transplant 26(9), 999
(2000): Maeno Y+, Respirology 5(4), 393
(1999): Ahuja M+, Am J Kidney Dis 34(3), 521 (with azathioprine)
(1999): Matsuda K+, J Gastroenterol 34(3), 390
(1998): Matsuno O+, Am J Trop Med Hyg 59(1), 42 (with
melphalan)
(1998): Yagi T+, Kekkaku 73(9), 557
(1996): Gallardo D+, Bone Marrow Transplant 18(6), 1135
Lipomatosis
(2000): Jalladeau E+, Rev Neurol (Paris) 156(5), 517
Myalgia/Myositis/Myopathy/Myotoxicity
(2003): Kumar S, Neurol India 51(4), 554
(2001): Walsh LJ+, Thorax 56(4), 279
Side effects (sic)
(2004): Potter JM+, Ther Drug Monit 26(4), 408
(2001): Macchia PE+, J Endocrinol Invest 24(3), 152
(2000): Eastell R+, Osteoporos Int 11(4), 331
(2000): Ozaki D+, J Nippon Med Sch 67(4), 271
Toxicity (sic)
(2000): Hiraoka M+, Kidney Int 58(3), 1247
Tumors
(2000): de Bono JS+, Ann Oncol 11(6), 749